Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Phathom Pharmaceuticals (PHAT) over the last 6 years, with Dec 2024 value amounting to $24.0 million.

  • Phathom Pharmaceuticals' Share-based Compensation rose 64.99% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year decrease of 28.96%. This contributed to the annual value of $24.0 million for FY2024, which is 46.59% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Share-based Compensation stood at $24.0 million for FY2024, which was down 46.59% from $45.0 million recorded in FY2023.
  • In the past 5 years, Phathom Pharmaceuticals' Share-based Compensation registered a high of $45.0 million during FY2023, and its lowest value of $5.8 million during FY2020.
  • In the last 3 years, Phathom Pharmaceuticals' Share-based Compensation had a median value of $24.1 million in 2022 and averaged $31.1 million.
  • In the last 5 years, Phathom Pharmaceuticals' Share-based Compensation spiked by 1,338.42% in 2020 and then tumbled by 46.59% in 2024.
  • Yearly analysis of 5 years shows Phathom Pharmaceuticals' Share-based Compensation stood at $5.8 million in 2020, then skyrocketed by 187.88% to $16.8 million in 2021, then spiked by 43.55% to $24.1 million in 2022, then soared by 86.57% to $45.0 million in 2023, then tumbled by 46.59% to $24.0 million in 2024.